EUVIMEDDescobrir EUVIMED
CrossrefCartão informativo

Endothelium-derived endothelin-1 mediates sickle cell nephropathy

Malgorzata Kasztan, Patrick A. Molina, Brandon M. Fox, Elizabeth Saurage, Jackson C. Colson, David M. Pollock, Jennifer S. Pollock

Function · 2026-04-01 · 7 (2)

DOI: 10.1152/function.001.2026 ↗
ResumoDados bibliográficos

Resumo

Sickle cell nephropathy (SCN) significantly shortens the life expectancy of patients with sickle cell disease (SCD). We previously reported that endothelin-1 (ET-1) and endothelin A receptor (ET A ) are upregulated in SCN, and ET A antagonism mitigates SCN early in the disease progression in a humanized mouse model of SCD. We hypothesized that endothelium-derived ET-1 mediates the progression of SCN and T cell inflammation in the kidney of SCD mice. To test this hypothesis, we first used allogenic bone marrow transplantation from humanized sickle cell mice (HbSS) into endothelial-derived ET-1 knockout (VEET KO) mice, revealing that endothelial-derived ET-1 mitigates SCN and regulates the renal inflammatory response and T cell infiltration. Second, using young (4–5 mo old) and middle-aged (10–15 mo old) HbSS mice lacking endothelial-specific ET-1 (HbSS-VEET KO), we found a temporal maintenance of glomerular filtration rate, reduced infiltration of T cells to the kidney, and reduced progression of SCN. Furthermore, 2-wk ET A antagonism in middle-aged HbSS mice reduced infiltration of T cells. Finally, flow cytometric analyses revealed blunting of kidney T helper 17 (T H 17) cells without a change in kidney T regulatory cells in HbSS-VEET KO mice, suggesting T cell subset-specific regulation by endothelial-derived ET-1 signaling. In vitro studies showed that ET A antagonism directly inhibits T H 17 polarization and IL-17A production, suggesting that in established sickle cell disease, the ET A receptor-T H 17 cell axis may play a key role in maintenance of fibrosis in SCN. Taken together, these data indicate that endothelial-derived ET-1 mediates the progression of SCN and strengthens the rationale for targeting ET-1 signaling as a new therapeutic approach.

Conhecimento que se adapta ao seu trabalho.

Do início gratuito e da pesquisa bibliográfica pessoal até à Research Suite completa.

Ver tarifas →

Todos os textos integrais das editoras estão incluídos?

Não. As referências bibliográficas, os resumos e os textos integrais são conteúdos diferentes. A disponibilidade de um texto integral depende da fonte, do Open Access e das licenças de que já dispõe. Um plano EUVIMED não substitui direitos adicionais de editor.

Ver tarifas →